1. Home
  2. PCQ vs IOVA Comparison

PCQ vs IOVA Comparison

Compare PCQ & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCQ
  • IOVA
  • Stock Information
  • Founded
  • PCQ 2001
  • IOVA 2007
  • Country
  • PCQ United States
  • IOVA United States
  • Employees
  • PCQ N/A
  • IOVA N/A
  • Industry
  • PCQ Investment Managers
  • IOVA Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • PCQ Finance
  • IOVA Health Care
  • Exchange
  • PCQ Nasdaq
  • IOVA Nasdaq
  • Market Cap
  • PCQ N/A
  • IOVA 1.0B
  • IPO Year
  • PCQ N/A
  • IOVA N/A
  • Fundamental
  • Price
  • PCQ $8.66
  • IOVA $1.73
  • Analyst Decision
  • PCQ
  • IOVA Strong Buy
  • Analyst Count
  • PCQ 0
  • IOVA 9
  • Target Price
  • PCQ N/A
  • IOVA $18.22
  • AVG Volume (30 Days)
  • PCQ 69.6K
  • IOVA 9.3M
  • Earning Date
  • PCQ 01-01-0001
  • IOVA 05-08-2025
  • Dividend Yield
  • PCQ 4.63%
  • IOVA N/A
  • EPS Growth
  • PCQ N/A
  • IOVA N/A
  • EPS
  • PCQ N/A
  • IOVA N/A
  • Revenue
  • PCQ N/A
  • IOVA $164,070,000.00
  • Revenue This Year
  • PCQ N/A
  • IOVA $182.20
  • Revenue Next Year
  • PCQ N/A
  • IOVA $62.10
  • P/E Ratio
  • PCQ N/A
  • IOVA N/A
  • Revenue Growth
  • PCQ N/A
  • IOVA 13698.99
  • 52 Week Low
  • PCQ $8.19
  • IOVA $2.70
  • 52 Week High
  • PCQ $10.50
  • IOVA $13.60
  • Technical
  • Relative Strength Index (RSI)
  • PCQ 53.74
  • IOVA 24.56
  • Support Level
  • PCQ $8.65
  • IOVA $3.02
  • Resistance Level
  • PCQ $8.80
  • IOVA $3.31
  • Average True Range (ATR)
  • PCQ 0.10
  • IOVA 0.24
  • MACD
  • PCQ 0.04
  • IOVA -0.08
  • Stochastic Oscillator
  • PCQ 81.67
  • IOVA 6.00

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Share on Social Networks: